Equity Analysis /
United States of America

US : ACADIA Pharmaceuticals Inc. - ACAD | FY21 Nuplazid Guidance Narrowed; FDA Feedback & Clarity on DRP Expected Near YE

    Danielle Brill
    CGS-CIMB
    9 November 2021
    Published by